General Endocrinology Feature Archive
Michael Pillinger, MD, professor of medicine at New York University School of Medicine, spoke with Rheumatology Advisor about his team's recent review of gout and metabolic syndrome.
One practicing endocrinologist ponders whether mentoring medical students requires more than imparting knowledge.
The role of uncertainty in clinical practice, and its implications for physicians, is thoughtfully examined by an endocrinologist in this opinion piece.
Although the underlying pathophysiology of homeostasis-related headaches is not yet clearly defined, the nervous and endocrine systems are thought to be involved through the maintenance of homeostasis.
Even the addition of a cash incentive did not result in significant health benefits for patients using activity trackers.
As our aging workforce expands, a decreasing number of young investigators are applying for National Institute of Health (NIH) R01-equivalent grants.
Decreased caloric intake was linked to improvements in mood, sleep quality, and sexual drive.
Although many clinicians applaud the big-picture approach of the new guidelines, some have taken issue with certain recommendations.
Consensus group focuses on prevention and treatment of exercise-associated hyponatremia.
Changes in adipose tissue precede the development of cachexia symptoms, and suggest a treatment approach.
Primarily used in food and drink packaging, ingestion of bisphenol A has been linked to obesity, diabetes and reproductive disorders.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Fatigue Management Contributes to Effective Endometriosis Care
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Trulicity Labeling Updated to Include Data on T2D Patients With CKD
- New Data Support Long-Term Cardiovascular Safety of Linagliptin in T2D
- Peer-Led Education Helps Physicians Save Time With EHRs
- As Immigration Policies Tighten, Physician Shortage Concerns Grow